M.J.B. Aarts - Essers

van Dijk, E. J., Nienhuis, H. H., van den Eertwegh, A. J. M., Boers-Sonderen, M. J., Bloem, M., Kamphuis, A. M., Ros, M. M., Bos, C., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., de Groot, J. W. B., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Stevense-den Boer, A. M., Vreugdenhil, G., Wouters, M. W. J. M., ... Suijkerbuijk, K. P. M. (2025). Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy. British Journal of Cancer. Advance online publication. https://doi.org/10.1038/s41416-025-03027-z

Yildirim, H., Aben, K. K. H., Bijlsma, M. J., Postema, A. W., Aarts, M. J. B., van Oijen, M. G. H., Bex, A., Bins, A. D., & Zondervan, P. J. (2025). A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. European Urology Oncology. Advance online publication. https://doi.org/10.1016/j.euo.2025.02.011

Bloem, M., de Meza, M. M., van den Eertwegh, A. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., Boreel, C. D. M., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., Piersma, D., Rikhof, B., Stevense-den Boer, A. M., van der Veldt, A. A. M., ... Wouters, M. W. J. M. (2025). Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis. British Journal of Cancer, Article 102290. Advance online publication. https://doi.org/10.1038/s41416-025-03021-5

Giannatempo, P., Machiels, J. P., Sassa, N., Arranz, J. A., Fujii, Y., Su, W. P., Keam, B., Culine, S., Shen, Y. C., Langa, J. M., Sarid, D., Aarts, M., Calabrò, F., Rosenbaum, E., Moreno, B. H., Bavle, A., Xu, J. Z., & Rha, S. Y. (2025). Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials. Clinical Genitourinary Cancer, 23(2), Article 102273. https://doi.org/10.1016/j.clgc.2024.102273

Klaver, K. M., Duijts, S. F. A., Geusgens, C. A. V., Aarts, M. J. B., Ponds, R. W. H. M., van der Beek, A. J., & Schagen, S. B. (2025). Internet-based cognitive rehabilitation for working cancer survivors: A process evaluation. Journal of Occupational and Environmental Medicine, 67(4), 268-277. https://doi.org/10.1097/JOM.0000000000003312

de Groot, S., Blommestein, H. M., Leeneman, B., Uyl-de Groot, C. A., Haanen, J. B. A. G., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blokx, W. A. M., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., & van Baal, P. H. M. (2025). Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced Melanoma. Medical Decision Making, 45(3), 302-317. https://doi.org/10.1177/0272989X251319338

Blommestein, H. M., de Groot, S., Leeneman, B., Uyl-de Groot, C. A., Haanen, J. B. A. G., Wouters, M. W. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blokx, W. A. M., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., van Not, O. J., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., & Franken, M. G. (2025). Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic model. European Journal of Cancer, 218, Article 115071. https://doi.org/10.1016/j.ejca.2024.115071

Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Bloem, M., Blokx, W. A. M., Boers-Sonderen, M. J., Bonenkamp, J. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Haanen, J. B., Holtslag, C. E., Hospers, G. A. P., Piersma, D., van Rijn, R. S., Stevense-den Boer, A. M., Suijkerbuijk, K. P. M., ... de Glas, N. A. (2025). Corrigendum to “Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry” [Eur. J. Cancer 212, 2024, 115056] (European Journal of Cancer (2024) 212, (S0959804924010220), (10.1016/j.ejca.2024.115056)). European Journal of Cancer, 216, Article 115194. https://doi.org/10.1016/j.ejca.2024.115194

Yildirim, H., Richters, A., Bins, A. D., Postema, A. W., Aarts, M. J. B., van Oijen, M. G. H., Zondervan, P. J., & Aben, K. K. H. (2025). Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort. European Urology Open Science, 72, 42-45. https://doi.org/10.1016/j.euros.2025.01.008

Leek, L. V. M., Notohardjo, J. C. L., de Joode, K., Velker, E. L., Haanen, J. B. A. G., Suijkerbuijk, K. P. M., Aarts, M. J. B., de Groot, J. W. B., Kapiteijn, E., van den Berkmortel, F. W. P. J., Westgeest, H. M., de Gruijl, T. D., Retel, V. P., Cuppen, E., van der Veldt, A. A. M., Labots, M., Voest, E. E., van de Haar, J., & van den Eertwegh, A. J. M. (2024). Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma. Scientific Reports, 14(1), Article 11244. https://doi.org/10.1038/s41598-024-61150-y